...
首页> 外文期刊>BJU international >Survival outcomes after radical and partial nephrectomy for clinical T2 renal tumours categorised by R.E.N.A.L. nephrometry score
【24h】

Survival outcomes after radical and partial nephrectomy for clinical T2 renal tumours categorised by R.E.N.A.L. nephrometry score

机译:R.E.N.A.L.分类的临床T2肾肿瘤的根治性和部分性肾切除术后的生存结果。肾功能评分

获取原文
获取原文并翻译 | 示例
           

摘要

Objective We evaluated survival outcomes of partial nephrectomy (PN) and radical nephrectomy (RN) for clinical T2 renal masses (cT2RM) controlling for R.E.N.A.L. nephrometry score. Patients and Methods A two-centre study comprised of 202 patients with cT2RM who underwent RN (122) or PN (80) between July 2002 and June 2012 (median follow-up 41.5 months). Kaplan-Meier analysis compared overall survival (OS), cancer-specific survival (CSS) and progression-free survival (PFS) among the entire cohort and within categories of R.E.N.A.L. nephrometry score of ≥10 and <10. Association between procedure and PFS and OS was analysed using Cox-proportional hazard. Results There were no significant differences between PN and RN in clinical T stage and R.E.N.A.L. nephrometry scores. For RN and PN, the 5-year PFS was 69.8% and 79.9% (P = 0.115), CSS was 82.5% and 86.7% (P = 0.407), and OS was 80% and 83.3% (P = 0.291). Cox regression showed no association between RN vs PN and PFS; a R.E.N.A.L. nephrometry score of ≥10 was associated with a shorter PFS (hazard ratio 6.69, P = 0.002). Kaplan-Meier analysis for RN vs PN showed no difference in PFS for entire cohort or within the R.E.N.A.L. nephrometry score categories of ≥10 and <10. The PFS was better for those with R.E.N.A.L nephrometry scores of <10 vs ≥10 (P < 0.001) and for cT2a vs cT2b tumours (P = 0.012). OS was no different between cT2a and cT2b tumours; patients with R.E.N.A.L. nephrometry scores of ≥10 were more likely to die from disease (P < 0.001) or any cause (P < 0.001) vs those with R.E.N.A.L. nephrometry scores of <10. Conclusions PN may be oncologically effective for cT2RM. A R.E.N.A.L nephrometry score of ≥10 is negatively associated with OS among cT2RM compared with a score of <10 and provides additional risk assessment beyond clinical T stage. Further follow-up and prospective randomised investigation is requisite to confirm efficacy of PN for cT2RM.
机译:目的我们评估了控制R.E.N.A.L.的临床T2肾肿块(cT2RM)的部分肾切除术(PN)和根治性肾切除术(RN)的生存结果。肾功能评分。患者和方法一项为期两中心的研究,包括202例2002年7月至2012年6月(中位随访41.5个月)接受RN(122)或PN(80)的cT2RM患者。 Kaplan-Meier分析比较了整个队列和R.E.N.A.L.类别中的总体生存期(OS),癌症特异性生存期(CSS)和无进展生存期(PFS)。肾功能评分≥10且<10。使用Cox比例风险分析程序与PFS和OS之间的关联。结果在临床T期和R.E.N.A.L. PN和RN之间无显着差异。肾功能评分。对于RN和PN,5年PFS为69.8%和79.9%(P = 0.115),CSS为82.5%和86.7%(P = 0.407),OS为80%和83.3%(P = 0.291)。 Cox回归显示RN与PN和PFS之间无关联; R.E.N.A.L.肾功能评分≥10与较短的PFS相关(危险比6.69,P = 0.002)。 Kaplan-Meier对RN与PN的分析显示,整个队列或R.E.N.A.L.中的PFS没有差异。肾功能评分得分类别≥10且<10。对于R.E.N.A.L肾功能检查得分<10 vs≥10(P <0.001)的患者以及cT2a vs cT2b肿瘤的患者(P = 0.012),PFS更好。 cT2a和cT2b肿瘤的OS无差异。 R.E.N.A.L.患者与R.E.N.A.L.相比,≥10的肾功能检查得分更有可能死于疾病(P <0.001)或任何原因(P <0.001)。肾功能评分<10。结论PN对cT2RM可能具有肿瘤学作用。 RT E.N.A.L肾功能评分≥10与cT2RM中的OS呈负相关,而评分<10则与临床T分期无关。进一步的随访和前瞻性随机研究对于确认PN对cT2RM的疗效至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号